.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 3,681,500

« Back to Dashboard

Claims for Patent: 3,681,500

Title: SPRAY COMPOSITIONS FOR TREATMENT OF OBSTRUCTIVE DISORDERS OF THE RESPIRATORY TRACT AND METHODS THEREFOR
Abstract:Inhalation spray compositions for the treatment of obstructive disorders of the respiratory tract, comprising as an active ingredient a physiologically compatible quaternary salt of N-isopropyl-N-methyl-nortropine tropic acid ester, optionally in combination with a mucolytic and/or a bronchospasmolytic.
Inventor(s): Zeile; Karl (Ingelheim am Rhein, DT), Schulz; Werner (Ingelheim am Rhein, DT), Banholzer; Rolf (Ingelheim am Rhein, DT), Wick; Helmut (Ingelheim am Rhein, DT)
Assignee: Boehringer Ingelheim GmbH (Ingelheim am Rhine, DT)
Application Number:05/094,951
Patent Claims: 1. The method of reducing the air flow resistance in the respiratory tract of a human patent afflicted with an asthmatic disorder of the respiratory tract, which comprises administering to said patient per inhalationem from 5 to 1,000 .gamma. of a pharmaceutically acceptable quaternary atropinium salt of the formula ##SPC1##

2. The method according to claim 8, where X is the anion of hydrobromic,

3. The method according to claim 8, where X is the anion of hydrobromic

4. The method according to claim 8, which comprises simultaneously administering to said patient per inhalationem and effective bronchospasmolytic amount of a bronchial antispasmodic selected from the group consisting of 1-(3',5'-dihydroxy-phenyl)-1-hydroxy-2-[1"-(p-hydroxy-phenyl)-isopropyl-am ino]-ethane hydrobromide and

5. The method according to claim 8, which comprises simultaneously administering to said patient per inhalationem an effective mucolytic amount of a compound selected from the group consisting of

6. A pharmaceutical inhalation spray composition for treating asthmatic disorders of the respiratory tract, consisting of 0.007 to 1.0 percent weight, based on the total weight of said composition, of a pharmaceutically acceptable quaternary atropinium salt of the formula ##SPC2##

wherein X is the anion of an acid, and the balance an aqueous solution of 2 mgm/ml of N-cyclohexyl-N-methyl-2-(2-amino-3,5-dibromo)-benzylammonium

7. A composition according to claim 6, wherein said atropinium salt is

8. A pharmaceutical inhalation spray composition for treating asthmatic disorders of the respiratory tract, consisting of 0.007 to 1.0 percent weight, based on the total weight of said composition, of a pharmaceutically acceptable quaternary atropinium salt of the formula ##SPC3##

wherein X is the anion of an acid, and the balance an aqueous solution of 0.2 mgm/ml of a mucolytic selected from the group consisting of

9. A composition according to claim 8, wherein said atropinium salt is

10. A pharmaceutical inhalation spray composition for treating asthmatic disorders of the respiratory tract, consisting essentially of an effective amount of a pharmaceutically acceptable quaternary atropinium salt of the formula ##SPC4##

11. A composition according to claim 10, wherein said non-aqueous liquid carrier is a liquified mixture of monofluoro-trichloro-methane and

12. A composition according to claim 10, wherein said atropinium salt is

13. A composition according to claim 10, which additionally comprises up to

14. A composition according to claim 13, which additionally comprises an effective bronchospasmolytic amount of 1-(3',5'-dhydroxy-phenyl)-1-hydroxy-2-[1"-(p-hydroxy-phenyl)-isopropyl-ami no]-ethan hydrobromide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc